Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2015 Oct;40(3):323-30.
doi: 10.1007/s11239-015-1180-z.

Association between micro particle-tissue factor activity, factor VIII activity and recurrent VTE in patients with acute pulmonary embolism

Judith Kooiman  1 , Paul L den Exter, Inci Kilicsoy, Suzanne C Cannegieter, Jeroen Eikenboom, Menno V Huisman, Frederikus A Klok, Henri H Versteeg
Affiliations
Clinical Trial

Association between micro particle-tissue factor activity, factor VIII activity and recurrent VTE in patients with acute pulmonary embolism

Judith Kooiman et al. J Thromb Thrombolysis. 2015 Oct.

Abstract

Studies on the association between microparticle expressing tissue factor (MP-TF) activity, FVIII activity (

Fviii: C) and recurrent VTE yielded inconclusive results. We studied these associations in patients diagnosed with acute pulmonary embolism. Plasma levels of MP-TF and FVIII activity were measured in 277 patients with a first and 72 patients with a recurrent VTE. All patients were categorized based on the quintiles of MP-TF and FVIII activity in those with a single VTE. For both markers, odds ratios (ORs) for recurrent VTE were computed using patients in the lowest quintile as a reference group. No association was observed between MP-TF activity and recurrent VTE, with an OR of 1.4 (95 % CI 0.7-2.9) in the highest quintile of MP-TF activity. Compared with the reference group, patients in the highest quintile of

Fviii: C were at increased risk of recurrent VTE, OR 4.2 (95 % CI 1.4-12.2). MP-TF activity was not associated with recurrent VTE whereas high

Fviii: C levels were associated with a 4-fold increased risk of VTE recurrence. Future prospective studies are necessary to explore the potential of

Fviii: C as a tool for risk stratification, either by itself or in combination with other pro-thrombotic markers.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Study design
Fig. 2
Fig. 2
Flow chart
See this image and copyright information in PMC

References

    1. Anderson FA, Jr, Wheeler HB, Goldberg RJ, Hosmer DW, Patwardhan NA, Jovanovic B, Forcier A, Dalen JE. A population-based perspective of the hospital incidence and case-fatality rates of deep vein thrombosis and pulmonary embolism. The Worcester DVT Study. Arch Intern Med. 1991;151:933–938. doi: 10.1001/archinte.1991.00400050081016. - DOI - PubMed
    1. Oger E. Incidence of venous thromboembolism: a community-based study in Western France. EPI-GETBP Study Group. Groupe d’Etude de la Thrombose de Bretagne Occidentale. Thromb Haemost. 2000;83:657–660. - PubMed
    1. Carrier M, Le Gal G, Wells PS, Rodger MA. Systematic review: case-fatality rates of recurrent venous thromboembolism and major bleeding events among patients treated for venous thromboembolism. Ann Intern Med. 2010;152:578–589. doi: 10.7326/0003-4819-152-9-201005040-00008. - DOI - PubMed
    1. Prandoni P, Lensing AW, Cogo A, Cuppini S, Villalta S, Carta M, Cattelan AM, Polistena P, Bernardi E, Prins MH. The long-term clinical course of acute deep venous thrombosis. Ann Intern Med. 1996;125:1–7. doi: 10.7326/0003-4819-125-1-199607010-00001. - DOI - PubMed
    1. Kearon C, Gent M, Hirsh J, Weitz J, Kovacs MJ, Anderson, Turpie AG, Green D, Ginsberg JS, Wells P, MacKinnon B, Julian JA. A comparison of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism. N Engl J Med. 1999;340:901–907. doi: 10.1056/NEJM199903253401201. - DOI - PubMed